No Data
No Data
Insider decrases its stake in AnGes(4563.JP) to 31.91%
On Oct 15, CANTOR FITZGERALD EUROPE submitted the Change Report to Ministry of Finance. The report shows that CANTOR FITZGERALD EUROPE decreased their holdings in $AnGes(4563.JP)$, with their joint
AnGes' genetic treatment product "Collategene" has been designated as a breakthrough therapy.
On the 10th, Anges <4563> announced the effects and prospects of the future development of the pharmaceutical "Colategene", which has been designated for breakthrough therapy. "Colategene" is a gene therapy product developed by the company in the usa, and has been designated as a breakthrough therapy by the Food and Drug Administration (FDA) in the usa. Breakthrough therapy aims to expedite the development and evaluation of drugs for the treatment of serious symptoms by the FDA.
Volume Change Rate Ranking (9 o'clock) - Kyukoh Yakuhin, Koshidaka HD, etc. are ranked.
In the volume change rate ranking, by comparing the volume of the most recent 5 days with the volume on the delivery day, you can understand the market participants' interests in trends such as stockpiling. Top volume change rate [as of 9:32 on October 11] (comparison with the most recent 5-day average volume) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate <2625> iFTPX Year 4 207,692 107,185.08 301.98% 0.00
Cocorara, OncoRis Bio, and others
Amita HD, a wholly-owned subsidiary of 2195, absorbs and merges with MIDAO. Silicon Studio of 3907 downward revised its current fiscal year operating profit forecast from 25.4 billion yen to 14.8 billion yen. Cocoonala of 4176 upward revised its previous fiscal year operating profit forecast from 27 billion yen to 30.4 billion yen. Anges' gene therapy product 'Collategen' has been designated as a breakthrough therapy. Oncolis Bio's 20th new subscription rights (with revision clause on exercise price) will see a large-scale exercise starting from the 1st.
AnGes Research Memo (7): Due to the decrease in research and development expenses, the accumulated operating loss for the second quarter of the fiscal year ending December 2024 has narrowed.
■ Performance trend of Anges <4563> 1. Performance overview for the cumulative second quarter of the fiscal year ending December 2024 Business revenue for the cumulative second quarter of the fiscal year ending December 2024 was 3.47 billion yen (an increase of 2.96 billion yen from the same period last year), operating loss was 5.107 billion yen (a decrease of 0.843 billion yen), ordinary loss was 3.19 billion yen (a decrease of 1.586 billion yen), and net loss for the quarter attributable to parent company shareholders was 3.5 billion yen (a decrease of 1.329 billion yen). Business revenue is related to rare genetic diseases.
Anges Research Memo (6): The policy is to provide one-stop testing for rare genetic diseases.
AnGes' ACRL initiative, which began in July 2021, for optional screening tests for rare genetic diseases has seen the number of tests increase from 0.01 million in December 2022 to 0.02 million in December 2023, and is expected to further expand to 0.04 to 0.05 million tests in December 2024 at more than double the pace. The commission income for the second quarter of the fiscal year ending December 2024 surged threefold year-on-year to 720 million yen, and is expected to continue to grow strongly from the third quarter onwards, with new initiatives in Gunma Prefecture.
No Data
No Data